MyFinsight
Home
Blog
About
Proceeds from sale of
common shares with...
$4,469K
Maturities of marketable
debt securities
$14,495K
(624.75%↑ Y/Y)
Proceeds from employee
options exercised
$6K
Net cash provided by
financing activities
$4,466K
(-5.72%↓ Y/Y)
Net cash provided by
investing activities
$3,960K
(109.63%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
$259K
(17.73%↑ Y/Y)
Canceled cashflow
$9K
Canceled cashflow
$10,535K
Net decrease in
cash, cash...
$1,441K
(140.26%↑ Y/Y)
Canceled cashflow
$7,244K
Payment of finance lease
liabilities
$9K
(-67.86%↓ Y/Y)
Stock-based compensation
$1,601K
(-34.79%↓ Y/Y)
Net loss
attributable to lineage
$1,482K
(104.28%↑ Y/Y)
Prepaid expenses and
other current assets
-$654K
(48.54%↑ Y/Y)
Depreciation and
amortization expense
$187K
(-44.18%↓ Y/Y)
Change in right-of-use
assets and liabilities
$62K
(170.45%↑ Y/Y)
Net income (loss)
attributable to...
$62K
(-35.42%↓ Y/Y)
Accounts receivable
-$19K
(95.01%↑ Y/Y)
Loss on disposal of
assets
-$19K
Purchases of marketable
debt securities
$10,427K
Purchase of equipment
$108K
(-2.70%↓ Y/Y)
Net cash used in
operating activities
-$7,244K
(30.51%↑ Y/Y)
Canceled cashflow
$4,086K
Change in fair value of
warrant liability
-$9,443K
(-190.49%↓ Y/Y)
Foreign currency
remeasurement
$749K
Deferred revenue
-$698K
(81.69%↑ Y/Y)
Accounts payable and
accrued liabilities
-$341K
(25.71%↑ Y/Y)
Accretion of income on
marketable debt securities
$99K
(890.00%↑ Y/Y)
Back
Back
Cash Flow
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)
source: myfinsight.com